Browsing by Author Paridaens, R.J.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialCoates, Alan; Campone, N; Castiglione-Gertsch, Monica; Forbes, John; Hawle, H; Mouridsen, Henning; Paridaens, R.J.; Price, K. N.; Rabaglio, Manuela; Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthBone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial, Annals of Oncology, vol.20, 9,pp 1489-1498
2012Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 TrialCoates, Alan; Bonnefoi, Herve; Ejlertsen, Bent; et al, Various; Ewertz, Marianne; Forbes, John F.; Gray, Kathryn P; Paridaens, R.J.; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Thurlimann, Beat; School of Public Health: Public HealthObesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial, Journal of Clinical Oncology, vol.30, 32, 2012,pp 3967-3975
2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Coates, Alan; Colleoni, Marco; Dell'Orto, Patrizia; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, A.; Gusterson,, B; Lang, Istvan; MacGrogan, G; Maiorano, Eugenio; Mastropasqua, M; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Price, Karen; Rasmussen, B; Regan, Meredith M.; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial., Annals of Oncology, vol.22, 10, 2011,pp 2201-7